← All trials
NCT04849559
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2021
- Primary completion
- Oct 31, 2021
- Completion date
- Oct 31, 2021
- First posted
- Apr 19, 2021
- Last posted
- Apr 19, 2021
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Vanda PharmaceuticalsLead sponsor
- Mayo ClinicCollaborator
- Vanda PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.